Page 20 - Demo
P. 20


                                    ANALESRANFwww.analesranf.comM, Tsiatis AC, Vibhakar R, Weiner S,Yi JS, Zheng F,Vassal G. Bromodomain and extra-terminal inhibitorsA consensus prioritisation after the Paediatric StrategyForum for medicinal product development ofepigenetic modifiers in children-ACCELERATE. Eur JCancer. 2021 Mar;146:115-124.21. Mellinghoff IK, van den Bent MJ, Blumenthal DT, Touat M,Peters KB, Clarke J, Mendez J, Yust-Katz S, Welsh L,Mason WP, Ducray F, Umemura Y, Nabors B, HoldhoffM, Hottinger AF, Arakawa Y, Sepulveda JM, Wick W,Soffietti R, Perry JR, Giglio P, de la Fuente M, MaherEA, Schoenfeld S, Zhao D, Pandya SS, Steelman L,Hassan I, Wen PY, Cloughesy TF; INDIGO TrialInvestigators. Vorasidenib in IDH1- or IDH2-MutantLow-Grade Glioma. N Engl J Med. 2023 Aug17;389(7):589-601.22. Esteller M, Pandolfi PP. The Epitranscriptome of NoncodingRNAs in Cancer. Cancer Discov. 2017 Apr;7(4):359-368.23. Davalos V, Blanco S, Esteller M. SnapShot: Messenger RNAModifications. Cell. 2018 Jul 12;174(2):498-498.e1.24. Esteve-Puig R, Bueno-Costa A, Esteller M. Writers, readersand erasers of RNA modifications in cancer. CancerLett. 2020 Apr 1;474:127-137.25. Berdasco M, Esteller M. Towards a druggableepitranscriptome: Compounds that target RNAmodifications in cancer. Br J Pharmacol. 2022Jun;179(12):2868- 2889.26. Yankova E, Blackaby W, Albertella M, Rak J, De BraekeleerE, Tsagkogeorga G, Pilka ES, Aspris D, Leggate D,Hendrick AG, Webster NA, Andrews B, Fosbeary R,Guest P, Irigoyen N, Eleftheriou M, Gozdecka M, DiasJML, Bannister AJ, Vick B, Jeremias I, Vassiliou GS,Rausch O, Tzelepis K, Kouzarides T. Small- moleculeinhibition of METTL3 as a strategy against myeloidleukaemia. Nature. 2021 May;593(7860):597-601.27. You Y, Fu Y, Huang M, Shen D, Zhao B, Liu H, Zheng Y,Huang L. Recent Advances of m6A DemethylasesInhibitors and Their Biological Functions in HumanDiseases. Int J Mol Sci. 2022 May 22;23(10):5815.Conflictos de inter%u00e9sDr Esteller es asesor de las compa%u00f1ias Ferrer, Incyte yQuimatryx; cuyas investigaciones no se describen en elart%u00edculo.F%u00e1rmacos Epigen%u00e9ticos y Epitranscript%u00f3micosManel Esteller Badosa 19 An. R. Acad. Farm.Vol. 90. n%u00ba 1 (2024) %u00b7 pp. 7-19Si desea citar nuestro art%u00edculo:F%u00e1rmacos Epigen%u00e9ticos y Epitranscript%u00f3micosManel Esteller BadosaAn Real Acad Farm (Internet).An. Real Acad. Farm.Vol. 90. n%u00ba 1 (2024) %u00b7 pp. 7-19DOI: http://dx.doi.org/10.53519/analesranf.2024.90.01.01
                                
   14   15   16   17   18   19   20   21   22   23   24